J&J MD&D segment sees 80 submissions in next two years

Johnson & Johnson's Medical Devices & Diagnostics segment has received more than a dozen regulatory approvals so far this year, and it plans to make approximately 80 significant submissions across its seven franchises between 2010 and 2012. In fact, the MD&D business segment, which generated $23.6 billion in sales in 2009 and became Johnson & Johnson's largest business segment, holds the No. 1 or 2 market positions in the majority of its markets. These facts were emphasized Thursday in a business review, during which Alex Gorsky, worldwide chair of MM&D, said the company is "very pleased, but not satisfied." Full story

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.